Evotec AG and Active Biotech AB Extend and Expand Medicinal Chemistry Collaboration

HAMBURG, Germany, April 26, 2012 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) today announced that it has extended and expanded its medicinal chemistry collaboration with Active Biotech AB (NASDAQ OMX: ACTI), to further advance an existing programme, which has entered the lead optimisation phase. The programme aims to find novel small molecule modulators of a priority biological target, selected by Active Biotech, involved in immune disorders and cancer.